Half-year report · HY
9627.TEDINET S100XAGJ
Period2025-05-01 → 2025-10-31
Filed2025-12-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥299.9bn | 2025-05-01 → 2025-10-31 | Cons. | Net sales |
| Revenue | ¥456.8bn | 2024-05-01 → 2025-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥214.9bn | 2024-05-01 → 2024-10-31 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2025-05-01 → 2025-10-31 | Cons. | Operating income |
| Operating income | ¥5.9bn | 2024-05-01 → 2024-10-31 | Cons. | Operating income |
| Ordinary income | ¥9.9bn | 2025-05-01 → 2025-10-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.1bn | 2024-05-01 → 2025-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.3bn | 2024-05-01 → 2024-10-31 | Cons. | Ordinary income |
| Profit before tax | ¥9.6bn | 2025-05-01 → 2025-10-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.7bn | 2024-05-01 → 2024-10-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.5bn | 2025-05-01 → 2025-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.3bn | 2024-05-01 → 2025-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.5bn | 2025-05-01 → 2025-10-31 | Cons. | Profit loss |
| Net income | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss |
| Total assets | ¥514.6bn | at 2025-10-31 | Cons. | Assets |
| Total assets | ¥311.9bn | at 2025-04-30 | Cons. | Assets |
| Total assets | ¥296.0bn | at 2024-10-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥369.1bn | at 2025-10-31 | Cons. | Liabilities |
| Total liabilities | ¥169.3bn | at 2025-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥145.5bn | at 2025-10-31 | Cons. | Net assets |
| Net assets / equity | ¥142.6bn | at 2025-04-30 | Cons. | Net assets |
| Net assets / equity | ¥136.1bn | at 2024-10-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥53.1bn | at 2025-10-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.9bn | at 2025-04-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥52.8bn | at 2025-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.7bn | at 2025-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.2bn | at 2024-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥48.4bn | at 2024-04-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.7bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥53.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥65.9bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥54.0bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥78.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥21.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥20.1bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥128.05 | 2025-05-01 → 2025-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥264.32 | 2024-05-01 → 2025-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.75 | 2024-05-01 → 2024-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.2% | at 2025-10-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2025-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.0% | at 2024-10-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-05-01 → 2025-10-31 | ¥5.7bn |
| Otherother segments | revenue external | 2025-05-01 → 2025-10-31 | ¥5.5bn |
| Otherother segments | revenue intersegment | 2025-05-01 → 2025-10-31 | ¥134m |
| Otherother segments | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥14m |
| Reconciling Itemsreconciling | revenue | 2025-05-01 → 2025-10-31 | −¥134m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-05-01 → 2025-10-31 | −¥134m |
| Reconciling Itemsreconciling | segment ordinary income | 2025-05-01 → 2025-10-31 | −¥6.5bn |
| Dispensing Pharmacyreportable segment | revenue | 2025-05-01 → 2025-10-31 | ¥254.7bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-05-01 → 2025-10-31 | ¥254.7bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥12.8bn |
| Drug And Cosmetic Storereportable segment | revenue | 2025-05-01 → 2025-10-31 | ¥39.6bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2025-05-01 → 2025-10-31 | ¥39.6bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥3.5bn |
| —segment total | revenue | 2025-05-01 → 2025-10-31 | ¥300.0bn |
| —segment total | revenue external | 2025-05-01 → 2025-10-31 | ¥299.9bn |
| —segment total | revenue intersegment | 2025-05-01 → 2025-10-31 | ¥134m |
| —segment total | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥16.4bn |
| Otherother segments | revenue | 2024-05-01 → 2024-10-31 | ¥5.6bn |
| Otherother segments | revenue external | 2024-05-01 → 2024-10-31 | ¥5.5bn |
| Otherother segments | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| Otherother segments | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥15m |
| Reconciling Itemsreconciling | revenue | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥5.0bn |
| Dispensing Pharmacyreportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥9.6bn |
| Drug And Cosmetic Storereportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥1.7bn |
| —segment total | revenue | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue external | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| —segment total | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥11.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 581
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)株式会社アインホールディングス | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)札幌市白石区東札幌５条２丁目４番30号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | InterimDuration | Text · Plus | |
| Notes changes in accounting policies na semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes accounting treatments specific to semi annual financial statements type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes additional information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | InterimInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | InterimDuration | Text · Plus | |
| Notes business combinations semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |